Lesson plan
CKD-506
CKD-506 is a histone deacetylase (HDAC) inhibitor which is under development for the treatment of inflammatory bowel diseases (IBDs) and rheumatoid arthritis. It acts as a selective HDAC6 inhibitor. The drug is taken orally.
Article summary
CKD-506 is a histone deacetylase (HDAC) inhibitor which is under development for the treatment of inflammatory bowel diseases (IBDs) and rheumatoid arthritis. It acts as a selective HDAC6 inhibitor. The drug is taken orally.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.